Sera Prognostics is a private biotechnology company developing diagnostic tests that use proprietary biomarkers that are predictive of preterm birth and other pregnancy complications. Sera was founded in 2008 and licensed its serum proteomics discovery technology and novel peptides from Brigham Young University and the University of Utah. The company has assembled a board of directors and management team with significant clinical development and womenâ€™s healthcare diagnostic experience for translating scientific innovation into commercial products that help patients and build significant corporate value. Sera is located in Salt Lake City, Utah.
Current Team (3)Update
Funding Rounds (5) - $44.6MUpdate
Osage University Partners is a venture capital fund investing in start-ups that commercialize...
Upstart Capital is a financial organization. Nothing is publicly known about the organization. If...
Early Stage Life science Investor
Founded in 1985, Domain Associates, L.L.C. is a venture capital firm with an exclusive focus on...
InterWest invests an average of about $7 - 15 million over the span of their involvement with...
417 Wakara Way
Salt Lake City, UT 84108